The role of tacrolimus in adult kidney transplantation: a review
Authors:
- 1 December 1998
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 12 (6) , 489-503
Abstract
The use of tacrolimus (FK506) in adult kidney‐transplant recipients has been the subject of a number of singleand multi‐center studies. This review article focuses on those studies in which tacrolimus was used either as rescue therapy in patients who developed refractory rejection on cyclosporine (CyA)‐based regimens or as primary immunosuppression in adult renal‐allograft recipients. Twenty‐five prospective and retrospective studies conducted in the US, Japan and Europe, including singleand multi‐center experiences, were identified in the medical literature. Of these studies, most show a 74‐98% initial success rate for tacrolimus rescue therapy. Comparative studies reviewed herein demonstrate comparable patientand graft‐survival rates between tacrolimusand CyA‐treated patients. Many studies have shown that rejection episodes occur with similar or lower frequency among patients treated with tacrolimus than among those given CyA as primary immunosuppression. The major toxicities associated with tacrolimus are nephrotoxicity, neurotoxicity and diabetogenicity. Results from several studies have also demonstrated an association between these tacrolimus side effects and high whole‐blood trough levels of tacrolimus. In many cases, a reduction in dosage can reverse these adverse effects. In summary, based on both singleand multi‐center data, tacrolimus has been demonstrated to be efficacious when used for either primary immunosuppression or as rescue therapy for refractory acute rejection in adult renal‐allograft recipients.Keywords
This publication has 16 references indexed in Scilit:
- Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literatureTransplantation Proceedings, 1997
- TACROLIMUS RESCUE THERAPY FOR RENAL ALLOGRAFT REJECTION-FIVE-YEAR EXPERIENCE1Transplantation, 1997
- AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATIONTransplantation, 1996
- TACROLIMUS THERAPY FOR REFRACTORY ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1996
- A MULTICENTER TRIAL OF FK506 (TACROLIMUS) THERAPY IN REFRACTORY ACUTE RENAL ALLOGRAFT REJECTIONTransplantation, 1996
- THE RELATIVE EFFECTS OF FK506 AND CYCLOSPORINE ON SHORT- AND LONG-TERM KIDNEY GRAFT SURVIVAL1,2,3Transplantation, 1995
- REVERSAL OF STEROID-RESISTANT REJECTION IN RENAL ALLOGRAFT RECIPIENTS USING FK506Transplantation, 1995
- A PROSPECTIVE RANDOMIZED TRIAL OF FK506-BASED IMMUNOSUPPRESSION AFTER RENAL TRANSPLANTATION1Transplantation, 1995
- FK506 “RESCUE” FOR RESISTANT REJECTION OF RENAL ALLOGRAFTS UNDER PRIMARY CYCLOSPORINE IMMUNOSUPPRESSION1Transplantation, 1994
- Haemolytic uraemic syndrome during FK506 therapyThe Lancet, 1992